Sunday, February 14, 2021 10:37:24 AM
Product TLC-2000 Therapeutic Medical Laser System, used for the temporary relief of knee pain.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRes/res.cfm?id=177458
-----------------------------Posted a bit ago @ $.173
TLTFF-0.076-TO-.173 nearly-tripled price in 8 weeks with .19-high
This stock will be in its 5 year range soon with breakout momentum!
Moving steadily toward the long held range on significant company milestones.
If you want shares below the longstanding 5 year range,
Ya might think about getting them soon.
(stock continues to approach 5 year range on increasing volume)
Major business milestones are being met. More are pending near term.
The USA Hospitals are lined up next!! One more hospital signed up.
The U.S. based Trial Management Organization plans to launch 4 to 5 clinical study sites in 4Q2020
_________________________________
Expect patient updates! Two more patients treated for a total of 14 in phase 2 and 2 in phase 1
As a Fast Track designee, Theralase® will have access to early and frequent communications with the FDA to discuss Theralase's development plans and ensure timely collection of the appropriate clinical data to support the approval process. The accelerated communication with the FDA potentially allows, TLD-1433, in combination with the TLC-3200 medical laser system ("TLC-3200"), to be the first intravesical patient-specific Ruthenium-based PDC for the treatment of patients with BCG-Unresponsive NMIBC CIS, with or without papillary Ta or T1 tumours. FTD can lead to an Accelerated Approval and Priority Review, if certain criteria are met, which the FDA has previously defined to the Company to represent approximately 20 to 25 patients enrolled and treated, who demonstrate significant safety and efficacy clinical outcomes.
https://theralase.com/theralase-granted-fda-fast-track-designation-for-nmibc-phase-ii-clinical-study/
November 23, 2020
______________________
Virus updates pending as well.
Lung updates are pending.
Brain cancer updates are pending.
JMO, maybe, maybe not.
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM